TY  - JOUR
AU  - Duering, Marco
AU  - Biessels, Geert Jan
AU  - Brodtmann, Amy
AU  - Chen, Christopher
AU  - Cordonnier, Charlotte
AU  - de Leeuw, Frank-Erik
AU  - Debette, Stéphanie
AU  - Frayne, Richard
AU  - Jouvent, Eric
AU  - Rost, Natalia S
AU  - Ter Telgte, Annemieke
AU  - Al-Shahi Salman, Rustam
AU  - Backes, Walter H
AU  - Bae, Hee-Joon
AU  - Brown, Rosalind
AU  - Chabriat, Hugues
AU  - De Luca, Alberto
AU  - deCarli, Charles
AU  - Dewenter, Anna
AU  - Doubal, Fergus N
AU  - Ewers, Michael
AU  - Field, Thalia S
AU  - Ganesh, Aravind
AU  - Greenberg, Steven
AU  - Helmer, Karl G
AU  - Hilal, Saima
AU  - Jochems, Angela C C
AU  - Jokinen, Hanna
AU  - Kuijf, Hugo
AU  - Lam, Bonnie Y K
AU  - Lebenberg, Jessica
AU  - MacIntosh, Bradley J
AU  - Maillard, Pauline
AU  - Mok, Vincent C T
AU  - Pantoni, Leonardo
AU  - Rudilosso, Salvatore
AU  - Satizabal, Claudia L
AU  - Schirmer, Markus D
AU  - Schmidt, Reinhold
AU  - Smith, Colin
AU  - Staals, Julie
AU  - Thrippleton, Michael J
AU  - van Veluw, Susanne J
AU  - Vemuri, Prashanthi
AU  - Wang, Yilong
AU  - Werring, David
AU  - Zedde, Marialuisa
AU  - Akinyemi, Rufus O
AU  - Del Brutto, Oscar H
AU  - Markus, Hugh S
AU  - Zhu, Yi-Cheng
AU  - Smith, Eric E
AU  - Dichgans, Martin
AU  - Wardlaw, Joanna M
TI  - Neuroimaging standards for research into small vessel disease-advances since 2013.
JO  - The lancet  / Neurology
VL  - 22
IS  - 7
SN  - 1474-4422
CY  - London
PB  - Lancet Publ. Group
M1  - DZNE-2023-00691
SP  - 602 - 618
PY  - 2023
AB  - Cerebral small vessel disease (SVD) is common during ageing and can present as stroke, cognitive decline, neurobehavioural symptoms, or functional impairment. SVD frequently coexists with neurodegenerative disease, and can exacerbate cognitive and other symptoms and affect activities of daily living. Standards for Reporting Vascular Changes on Neuroimaging 1 (STRIVE-1) categorised and standardised the diverse features of SVD that are visible on structural MRI. Since then, new information on these established SVD markers and novel MRI sequences and imaging features have emerged. As the effect of combined SVD imaging features becomes clearer, a key role for quantitative imaging biomarkers to determine sub-visible tissue damage, subtle abnormalities visible at high-field strength MRI, and lesion-symptom patterns, is also apparent. Together with rapidly emerging machine learning methods, these metrics can more comprehensively capture the effect of SVD on the brain than the structural MRI features alone and serve as intermediary outcomes in clinical trials and future routine practice. Using a similar approach to that adopted in STRIVE-1, we updated the guidance on neuroimaging of vascular changes in studies of ageing and neurodegeneration to create STRIVE-2.
KW  - Humans
KW  - Neurodegenerative Diseases
KW  - Activities of Daily Living
KW  - Neuroimaging
KW  - Magnetic Resonance Imaging: methods
KW  - Brain: diagnostic imaging
KW  - Cognitive Dysfunction
KW  - Cerebral Small Vessel Diseases: diagnostic imaging
LB  - PUB:(DE-HGF)16
C6  - pmid:37236211
DO  - DOI:10.1016/S1474-4422(23)00131-X
UR  - https://pub.dzne.de/record/258919
ER  -